Report
Will these 4 new drugs re-shape the market?
Get the latest in this quarter’s Drug Pipeline Insights Report.
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: March 2022
In this latest Drug Pipeline Insights Report, Optum Rx highlights the four medications expected by the end of the second quarter of 2022. While these new drugs might be safer and more effective, they come at a cost.
The drugs in this report include treatments for:
- A rare heart condition
- Plaque psoriasis
- Type 2 diabetes
- A cardiovascular disease characterized by an abnormally thick heart muscle
Don't want to read the full report? Download the brief summary.
Related content
4 more psoriasis drugs on the way
Psoriasis costs up 40% in 5 years. Will these drugs help?
5 questions: Optum Rx chief pharmacy officer
Michael Einodshofer addresses the risks, challenges and opportunities facing the industry.
The FDA & Alzheimer’s: What’s Next? | Optum Rx
Learn how Aduhelm’s approval could impact future drug approvals.
Top